AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 20- 52-wk high
- $62.32
- 52-wk low
- $14.79
- Prev close
- $41.25
- Mkt cap
- $4.35B
- Beta
- 0.24
- P/B
- 4.9x
Smart money
Earnings
Earnings came in 7.3% above what analysts expected.
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | — | $46.0K | $14.0K | — |
| Gross profit | — | -$46.0K | -$14.0K | — |
| What it spent | ||||
| Research and development | $18.2M | $21.2M | $20.7M | $29.0M |
| Sales and admin | $6.9M | $13.0M | $7.1M | $8.2M |
| Total operating expenses | $25.1M | $34.2M | $27.8M | $37.2M |
| What was left | ||||
| Operating profit | -$25.1M | -$34.3M | -$27.8M | -$37.2M |
| Profit before tax | -$20.1M | -$29.7M | -$23.6M | -$32.5M |
| Net profit | -$20.1M | -$29.7M | -$23.6M | -$32.5M |
| EBITDA | -$20.1M | -$29.6M | -$23.6M | -$32.5M |
Technicals
Price structure
No data yet
Technicals sync when verified market data is available. No sample data is shown.
News
What the news says
19 articles · 7 days
Coverage leans bullish
Tone of tracked coverage
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
NeutralAug 15Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
BullishAug 13Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN
NeutralAug 13
